Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elliott Ergon"'
Autor:
Will Paces, Elliott Ergon, Elizabeth Bueche, G. Dave Young, Vitria Adisetiyo, Cris Luengo, Meredith James, Charles Caldwell, Dannah Miller, Morgan Wambaugh, Geoffrey Metcalf, Roberto Gianani
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract PD-L1 (22C3) checkpoint inhibitor therapy represents a mainstay of modern cancer immunotherapy for non-small cell lung cancer (NSCLC). In vitro diagnostic (IVD) PD-L1 antibody staining is widely used to predict clinical intervention efficacy
Externí odkaz:
https://doaj.org/article/fcfbd68415114c36b101185dfdc94015
Autor:
Elliott Ergon, Kristin Shotts, Will Paces, Charles W. Caldwell, Roberto Gianani, Vitria Adisetiyo
Publikováno v:
Regular and young investigator award abstracts.
Background Determination of programmed death-ligand 1 (PD-L1) level in tumor by immunohistochemistry (IHC) is widely used to predict response to check point inhibitor therapy. In particular, the Dako PD-L1 (22C3) antibody is a common companion diagno
Publikováno v:
Cancer Research. 81:435-435
The Dako PD-L1 (22C3) antibody is used in immunohistochemistry (IHC) to measure tumor programmed death-ligand 1 (PD-L1) levels, serving as a common companion diagnostic to the check point inhibitor drug pembrolizumab in non-small cell lung cancer (NS
Publikováno v:
Journal of Clinical Oncology. 39:e18031-e18031
e18031 Background: The programmed death-ligand 1 (PD-L1) (22C3) antibody is a companion diagnostic to the check-point inhibitor drug pembrolizumab for head and neck squamous cell carcinoma (HNSCC). Specifically, PD-L1 expression, as determined by a C
Autor:
Kelsey Weigel, Will Paces, Elliott Ergon, Jeni Caldara, Kile McFadden, Cris Luengo, Roberto Gianani, Bharathi Vennapusa
Publikováno v:
Cancer Research. 79:4918-4918
Understanding response to immunotherapy requires accurate and complete characterization of tumor-associated immune cells in order to fully contextualize the immuno-oncology biomarker expression. Current standard practices surrounding enumeration of b
Publikováno v:
Cancer Research. 79:4923-4923
In vitro diagnostic (IVD) approvals of qualitative immunohistochemical (IHC) assays offer unique patient selection strategies by equipping pathologists with new tools to assess tumor status including tumor immune landscape. PD-L1/PD-1 checkpoint ther
Autor:
Joseph S. Krueger, Brad Foulk, Rengasamy Boominathan, Navi Mehra, Carsten Schnatwinkel, Kirti Sharma, Tatiana Perova, Denis Smirnov, Chandra Rao, Elliott Ergon, Karl Calara-Nielsen
Publikováno v:
Cancer Research. 78:3037-3037
Introduction: Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches are available and offer great insigh
Autor:
Joseph S. Krueger, Karen A. Ryall, Harney Allison S, Nathan T. Martin, Kristin Wilson, Janet C. Patterson-Kane, Brooke Hirsch, Will Paces, Famke Aeffner, Daniel G. Rudmann, Elliott Ergon
Publikováno v:
Cancer Research. 77:1674-1674
Quantification of tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancers (NSCLC) is valuable for understanding patient prognosis and survival. TILs comprise a subset of tumor-infiltrating leukocytes that modulate immune evasion and resp